Tuberculosis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mashal Awais, M.D.[2]; Alejandro Lemor, M.D. [3]

Overview[edit | edit source]

Secondary prevention for tuberculosis refers to the methods that are used for screening and early diagnosis, such as tuberculin skin test (TST) and IGRAs; as well as ensuring that the right treatment regimen is given at the right time to prevent disease progression.

Secondary Prevention[edit | edit source]

Screening[edit | edit source]

Tuberculin Skin Test[edit | edit source]

• Evaluation of children who are having close contact with a confirmed case of TB.
• TST is the test of choice for screening for TB infection.

Interferon-Gamma Release Assays (IGRAs)[edit | edit source]

• IGRA can be used in place of (but not in addition to) TST in screening for M. tuberculosis infection in the following conditions:^[1]

• A patient has received BCG vaccination
• Groups with poor follow up return for TST reading

• TST is favored over IGRA for TB screening due to its low cost and high availability^[2]

Early Diagnosis[edit | edit source]

• Early diagnosis of tuberculosis disease is essential to give the right treatment at the appropriate time and prevent complications.
• All patients should be routinely asked about:^[3]

• History of TB exposure, infection, or disease
• Symptoms or signs of TB disease
• Medical conditions that increase their risk for TB disease

• Patients with the following characteristics should be tested for tuberculosis:^[3]

• Cough for ≥3 weeks
• Loss of appetite
• Unexplained weight loss
• Night sweats
• Hemoptysis
• Hoarseness
• Fever
• Fatigue
• Chest pain
• Patient from an endemic area of TB

Prompt Treatment[edit | edit source]

• Empiric therapy should be started once the diagnosis of TB is confirmed.
• Sputum specimens should be sent for culture and DST before initiation of therapy

References[edit | edit source]

Template:WH Template:WS